San Diego-based biopharmaceuticals firm Sangart has raised $50M in a Series G funding round, the company announced Thursday, bringing its total venture funds raised to $280M. Sangart, which is developing biopharmaceuticals to treat hemorrhagic shock injury, said the new funds came from existing investor Leucadia National Corporation. The firm said the funding will go towards advancing development of its medicines, which are currently in Phase 2b studies. More information »